ARCTURUS THERAPEUTICS HOLDINGS INC. Operating Cash Flow
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Operating Cash Flow of -$39.35 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- ARCTURUS THERAPEUTICS HOLDINGS INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$19.91M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$19.44M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$16.23M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$17.15M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. net cash provided by (used in) operating activities for fiscal 2025 was -$74.27M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. net cash provided by (used in) operating activities for fiscal 2024 was -$59.75M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. net cash provided by (used in) operating activities for fiscal 2023 was -$18.10M, a 156.57% decline from fiscal 2022.
- ARCTURUS THERAPEUTICS HOLDINGS INC. net cash provided by (used in) operating activities for fiscal 2022 was $31.99M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$19.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$39.35M 10-Q · filed 2026-08-06 | -$55.58M derived: sum of 3 quarters · filed 2026-08-06 | -$72.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$19.44M 10-Q · filed 2026-05-07 | -$35.67M derived: sum of 2 quarters · filed 2026-05-07 | -$52.82M derived: sum of 3 quarters · filed 2026-05-07 | -$58.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$16.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$33.38M derived: sum of 2 quarters · filed 2026-03-03 | -$39.13M derived: sum of 3 quarters · filed 2026-08-06 | -$74.27M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$17.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$22.91M derived: sum of 2 quarters · filed 2026-08-06 | -$58.04M 10-Q · filed 2025-11-12 | -$58.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$5.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$40.89M 10-Q · filed 2026-08-06 | -$41.18M derived: sum of 3 quarters · filed 2026-08-06 | -$64.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$35.14M 10-Q · filed 2026-05-07 | -$35.42M derived: sum of 2 quarters · filed 2026-05-07 | -$59.19M derived: sum of 3 quarters · filed 2026-05-07 | -$89.33M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$284.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$24.05M derived: sum of 2 quarters · filed 2026-03-03 | -$54.19M derived: sum of 3 quarters · filed 2026-03-03 | -$59.75M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$23.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$53.91M derived: sum of 2 quarters · filed 2025-11-12 | -$59.46M 10-Q · filed 2025-11-12 | -$60.09M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | -$30.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$35.70M 10-Q · filed 2025-08-11 | -$36.33M derived: sum of 3 quarters · filed 2026-03-03 | -$68.73M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | -$5.56M 10-Q · filed 2025-05-12 | -$6.19M derived: sum of 2 quarters · filed 2026-03-03 | -$38.59M derived: sum of 3 quarters · filed 2026-03-03 | $12.21M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | -$629.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$33.03M derived: sum of 2 quarters · filed 2026-03-03 | $17.77M derived: sum of 3 quarters · filed 2026-03-03 | -$18.10M 10-K · filed 2026-03-03 |
| 2023-09-30 | -$32.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $18.40M derived: sum of 2 quarters · filed 2024-11-07 | -$17.47M 10-Q · filed 2024-11-07 | $142.79M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $50.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $14.94M 10-Q · filed 2024-08-05 | $175.19M derived: sum of 3 quarters · filed 2025-03-06 | $132.79M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | -$35.87M 10-Q · filed 2024-05-08 | $124.39M derived: sum of 2 quarters · filed 2025-03-06 | $81.98M derived: sum of 3 quarters · filed 2025-03-06 | $45.16M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $160.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $117.85M derived: sum of 2 quarters · filed 2025-03-06 | $81.03M derived: sum of 3 quarters · filed 2025-03-06 | $31.99M 10-K · filed 2025-03-06 |
| 2022-09-30 | -$42.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$79.23M derived: sum of 2 quarters · filed 2023-11-14 | -$128.27M 10-Q · filed 2023-11-14 | -$170.76M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | -$36.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$85.86M 10-Q · filed 2023-08-07 | -$128.36M derived: sum of 3 quarters · filed 2024-03-14 | -$145.01M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | -$49.04M 10-Q · filed 2023-05-09 | -$91.54M derived: sum of 2 quarters · filed 2024-03-14 | -$108.19M derived: sum of 3 quarters · filed 2024-03-14 | -$141.13M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | -$42.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$59.15M derived: sum of 2 quarters · filed 2024-03-14 | -$92.09M derived: sum of 3 quarters · filed 2024-03-14 | -$135.04M 10-K · filed 2024-03-14 |
| 2021-09-30 | -$16.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$49.60M derived: sum of 2 quarters · filed 2022-11-09 | -$92.55M 10-Q · filed 2022-11-09 | -$99.18M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$32.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$75.89M 10-Q · filed 2022-08-09 | -$82.53M derived: sum of 3 quarters · filed 2022-08-09 | -$98.40M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$42.95M 10-Q · filed 2022-05-09 | -$49.58M derived: sum of 2 quarters · filed 2022-05-09 | -$65.46M derived: sum of 3 quarters · filed 2022-05-09 | -$73.95M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$6.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$22.51M derived: sum of 2 quarters · filed 2022-03-01 | -$31.00M derived: sum of 3 quarters · filed 2022-03-01 | -$42.86M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$15.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$24.37M derived: sum of 2 quarters · filed 2021-11-09 | -$36.23M 10-Q · filed 2021-11-09 | -$43.77M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$8.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$20.35M 10-Q · filed 2021-08-10 | -$27.89M derived: sum of 3 quarters · filed 2022-03-01 | -$30.73M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$11.86M 10-Q · filed 2021-05-10 | -$19.40M derived: sum of 2 quarters · filed 2022-03-01 | -$22.23M derived: sum of 3 quarters · filed 2022-03-01 | -$12.89M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$7.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$10.37M derived: sum of 2 quarters · filed 2022-03-01 | -$1.03M derived: sum of 3 quarters · filed 2022-03-01 | -$6.45M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$2.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $6.50M derived: sum of 2 quarters · filed 2020-11-09 | $1.09M 10-Q · filed 2020-11-09 | -$4.67M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $9.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $3.93M 10-Q · filed 2020-08-10 | -$1.83M derived: sum of 3 quarters · filed 2021-03-01 | -$8.63M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$5.41M 10-Q · filed 2020-05-08 | -$11.17M derived: sum of 2 quarters · filed 2021-03-01 | -$17.97M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2018-12-31 | -$5.76M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$12.56M derived: sum of 2 quarters · filed 2021-03-01 | -$20.76M 10-K · filed 2021-03-01 | |
| 2018-09-30 | -$6.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$15.00M 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | -$8.20M 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |